Executive Chair and CEO

Director

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

Institution	Shares	Value	Change
BlackRock	8,397,642	$932M	INCREASED
State Street	2,500,696	$277M	INCREASED
Reinhart Partners, LLC	1,599,379	$177M	INCREASED
Swedbank AB	1,201,243	$133M	DECREASED
Assenagon Asset Management	714,980	$79M	INCREASED

Insider	Type	Shares	Value	Date
Mary Anne Heino (Executive Chair and CEO)	SELL	1,227	$119K	2026-05-14
Gerard Ber (Director)	SELL	381	$37K	2026-05-14
Julia Marie Eastland (Director)	AWARD	4,137		2026-05-14
James H Thrall (Director)	AWARD	4,137		2026-05-14
Gerard Ber (Director)	AWARD	4,137		2026-05-14

Lantheus Holdings, Inc (LNTH) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades